Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study

@article{Hulhoven2007LevocetirizineDN,
  title={Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study},
  author={R{\'e}ginald Hulhoven and Dominique Rosillon and Michel Letiexhe and Marie-Anne Meeus and Agn{\`e}s Daoust and Armel Stockis},
  journal={European Journal of Clinical Pharmacology},
  year={2007},
  volume={63},
  pages={1011-1017}
}
ObjectiveTo conduct a thorough QT study of levocetirizine, a non-sedating antihistamine, in accordance with International Conference on Harmonisation (ICH) E14 guidance.MethodsThe study was designed as a single-dose, placebo and positive-controlled, four-way crossover, randomised trial in which 52 healthy male and female subjects participated. Levocetirizine (5 and 30 mg) and placebo were administered double-blind, and the positive control, moxifloxacin (400 mg), was open-label… Expand
Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
TLDR
This study has demonstrated the utility of levofloxacin on the assay in measuring mean QTc changes around 5 ms and suggests the potential for use in more rigorous QT/QTc studies. Expand
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.
TLDR
This 'thorough QT/QTc study' confirmed previous experience with rupatadine and demonstrated that it had no proarrhythmic potential and raised no concerns regarding its cardiac safety. Expand
Effect of brivaracetam on cardiac repolarisation – a thorough QT study*
TLDR
The study was found to be valid in terms of assay sensitivity and the results demonstrated the absence of effects of brivaracetam on cardiac repolarisation, suggesting that no intensive cardiac monitoring is required during the subsequent stages of bri varacetam development. Expand
A thorough QT study of guanfacine.
TLDR
Guanfacine does not appear to interfere with cardiac repolarization of the form associated with pro-arrhythmic drugs, and neither therapeutic nor supra-therapeutic doses of guanfacine prolonged QT interval after adjusting for heart rate using individualized correction. Expand
Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT‐Concentration Analysis
TLDR
Moxifloxacin was associated with a significant increase in QTcNi at all time points between 1 and 12 hours, inclusively, and this result was most likely related to the cardiac effect of ketoconazole. Expand
Thorough QT/QTc Study in Patients With Advanced Parkinson's Disease: Cardiac Safety of Rotigotine
TLDR
Rotigotine in supra‐ and therapeutic doses was shown not to affect cardiac repolarization and accurate, thorough QTc studies are possible even in patients with diseases that profoundly affect ECG quality. Expand
Period Correction of the QTc of Moxifloxacin With Multiple Predose Baseline ECGs Is the Least Variable of 4 Methods Tested
This study compares 4 baseline correction methods on the effect of moxifloxacin on the QT/QTc interval: (1) day −1 time‐matched baseline electrocardiograms (ECGs), (2) 3 triplicate predose ECGs, (3)Expand
Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
TLDR
The utility of the telemetered cynomolgus monkey as a preclinical predictor of QTc) prolongation is exemplified and the rate of onset of hERG channel blockade observed in patch clamp offers a mechanistic insight into the relative rates of channel blockade seen in vivo with both Moxifloxacin and Dofetilide. Expand
Highly Automated QT Measurement Techniques in 7 Thorough QT Studies Implemented under ICH E14 Guidelines
  • J. Couderc, C. Garnett, +5 authors W. Zareba
  • Medicine
  • Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
  • 2011
TLDR
A validation of a highly automatic QT interval measurement (HA‐QT) method is proposed to evaluate potential effect of a novel drug on the ventricular repolarization process of the heart using QTc prolongation as a surrogate marker for torsades de pointes. Expand
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14
TLDR
Evidence is provided that careful QT assessment in early phase clinical studies can be used as an alternative to the thorough QT study, and clinical and regulatory implications, as well as limitations of this approach are discussed in the commentary. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.
TLDR
An approach to interpretation of the resulting ECG data from the trial and proper selection of the sample size, frequency of and method to analyze ECGs are provided. Expand
Drugs, QTc Interval Prolongation and Final ICH E14 Guideline
TLDR
A commentary on some of the challenges that are likely to be faced by the sponsors of drugs during the next few years of application of these two guidelines is provided. Expand
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.
TLDR
Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval and should be avoided. Expand
Second-generation antihistamines: the risk of ventricular arrhythmias.
TLDR
The data indicate that the potential to cause ventricular arrhythmias is not a class effect of second-generation antihistamines and that loratadine, cetirizine, azelastine, and fexofenadine are not associated with torsades de pointes or other ventriculararrhythias. Expand
Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study.
TLDR
The model suggests that administration of levocetirizine 0.125 mg kg(-1) twice daily in children 12-48 months of age or weighing 8-20 kg yields the same exposure as in adults taking the recommended dose of 5 mg once daily. Expand
Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy Subjects
TLDR
The pharmacokinetic parameters derived from compartmental and noncompartmental analyses were in good agreement and the kinetics could be described best by fitting the data to a two-compartment body model. Expand
Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline
TLDR
The studies described in S7B and E14 will contribute to a better understanding of the link between nonclinical assays and QT prolongation in humans and how predictive a negative thorough QT study result is for proarrhythmic risk in patients. Expand
Investigating Drug-Induced QT and QTc Prolongation in the Clinic: A Review of Statistical Design and Analysis Considerations: Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team
TLDR
It is recommended that the statistical rigor of the International Conference on Harmonisation guidance currently in development for clinical assessment be enhanced and that further research be conducted in the choice of endpoints, testing of hypotheses, and interpretation of QT and QTc data. Expand
Focus on issues in measuring and interpreting changes in the QTc interval duration
TLDR
Core ECG laboratories, with cardiovascular expertise, state-of-the-art information management technologies, and ECG reading systems, which are validated, quality assured, and constantly audited, can cost-eectively manage a product’s entire ECG safety programme. Expand
Pharmacokinetics, Safety and Tolerability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, after Repeated Oral Administration
TLDR
D dosage regimen of 400mg given once daily should be effective and well tolerated for the treatment of various infections, based on the safety profile and the pharmacokinetic behaviour of moxifloxacin. Expand
...
1
2
3
...